Skip to main content
. 2024 Mar 6;14:1334915. doi: 10.3389/fonc.2024.1334915

Figure 1.

Figure 1

Anti-tumor pathways mediated by APS. APS, Astragalus polysaccharides; SIRT1, Silent mating type information regulation 2 homolog- 1; AMPK, Adenosine monophosphate activated protein kinase; SREBP1, Recombinant Sterol Regulatory Element Binding Transcription Factor 1; BECN1,Beclin-1; xCT, Light chain subunit SLC7A11; GPX4,Glutathione peroxidase 4; JAK, Janus kinase; STAT, Signal transducer of activators of transcription; SHP2, SH2 domain-containing protein tyrosine phosphatase 2; SOCS3, Suppressor of cy-tokine signaling proteins; AKT, Protein kinase B; NF-κB, Nuclear factor kappa-B; p53, p53 protein; p21, p21 protein; Cyt-c, Cytochrome c; Bcl-2, B-cell lymphoma-2; Bax, Bcl-2-associated X; FBXW7, F-box/WD repeat-containing protein 7; JNK, c-Jun N-terminal kinases; EMT, Epithelial-mesenchymal transition; MIF, Macrophage migration inhibitor factor; VEGF, Vascular endothelial growth factor; EGFR, Epidermal growth factor receptor; p63, p63 protein; PI3K, Phosphatidylinositol-3-kinase; mTOR, Mammalian rapamycin target protein; LC3B, Microtubule-associated protein 1 light chain 3 Beta.